Iridex Corporation to Announce Third Quarter 2025 Financial Results and Business Update on November 11

Iridex Corporation will announce Q3 2025 financial results and updates on November 11, 2025, with a conference call.

Quiver AI Summary

Iridex Corporation, a leader in laser-based medical systems for ophthalmology, announced that it will release its financial results for the third quarter of 2025 and provide a business update on November 11, 2025, after market close. The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET, which investors can access by calling designated numbers and using a specific Conference ID. Iridex specializes in innovative technologies for treating glaucoma and retinal diseases, with its products used in over 100 countries. More information can be found on their website.

Potential Positives

Announcement of third-quarter financial results and business update may indicate transparency and commitment to shareholder communication.
Conference call presence shows willingness to engage directly with investors and address any questions regarding company performance.
Highlighting proprietary MicroPulse® technology emphasizes Iridex's innovation and leadership in the ophthalmology market, potentially attracting investor interest.
Global sales presence in over 100 countries suggests strong market penetration and potential for growth in international markets.

Potential Negatives

Timing of the financial results release may indicate that the company is experiencing delays or issues that could negatively impact their quarterly performance.
Announcement does not provide any preliminary insights or expectations about financial results, which may increase uncertainty for investors.

FAQ

What are Iridex Corporation's financial results release dates?

Iridex Corporation plans to release its financial results for Q3 2025 on November 11, 2025.

What time is the Iridex conference call scheduled?

The conference call will begin at 2:00 p.m. PT / 5:00 p.m. ET on November 11, 2025.

How can I access the Iridex conference call?

Investors can dial +1-888-596-4144 from the US or +1-646-968-2525 internationally to join the call.

Where can I find the Iridex Q3 2025 webcast?

A live and recorded webcast will be available on the “Event Calendar” page of Iridex's website.

What technologies does Iridex Corporation specialize in?

Iridex specializes in laser-based medical systems for treating glaucoma and retinal diseases using its MicroPulse® technology.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$IRIX Insider Trading Activity

$IRIX insiders have traded $IRIX stock on the open market 77 times in the past 6 months. Of those trades, 77 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $IRIX stock by insiders over the last 6 months:

WILLIAM M MOORE has made 7 purchases buying 99,234 shares for an estimated $105,514 and 0 sales.
ROMEO R DIZON (Chief Financial Officer) has made 69 purchases buying 34,350 shares for an estimated $42,206 and 0 sales.
PATRICK MERCER (President and CEO) purchased 250 shares for an estimated $240

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$IRIX Hedge Fund Activity

We have seen 5 institutional investors add shares of $IRIX stock to their portfolio, and 15 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

AMH EQUITY LTD removed 328,541 shares (-63.4%) from their portfolio in Q2 2025, for an estimated $289,740
ARS INVESTMENT PARTNERS, LLC removed 110,060 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $97,061
THOMPSON DAVIS & CO., INC. added 56,726 shares (+inf%) to their portfolio in Q2 2025, for an estimated $50,026
CITADEL ADVISORS LLC removed 43,077 shares (-58.0%) from their portfolio in Q2 2025, for an estimated $37,989
SUSQUEHANNA INTERNATIONAL GROUP, LLP added 38,636 shares (+inf%) to their portfolio in Q2 2025, for an estimated $34,073
BLACKROCK, INC. removed 36,408 shares (-64.2%) from their portfolio in Q2 2025, for an estimated $32,108
CONCURRENT INVESTMENT ADVISORS, LLC removed 21,944 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $19,352

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

MOUNTAIN VIEW, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced plans to release financial results for the third quarter 2025 and provide a business update after the close of trading on Tuesday, November 11, 2025.

The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 from the US or +1-646-968-2525 internationally and providing Conference ID: 1504499 followed by pressing #. A live and recorded webcast will be available on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com.

About Iridex Corporation

Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse ^® technology delivers a differentiated laser treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.

Investor Relations Contact:
Philip Taylor
Gilmartin Group
[email protected]